GNBT News and Press, Generex Biotechnology From 11/04/20

Generex Biotechnology ([[GNBT]]) signed a Framework Agreement with the China CDC, Beijing Guoxin Haixiang Equity Investment Partnership, and Beijing Youfeng International Consulting for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China....

Framework agreement outlines structure for project contracts: Ii-Key Vaccine for COVID-19 Ii-Key Vaccine for Swine Flu Ii-Key Platform for Cancer and Infectious Diseases Impending contract to establish a Cancer Research Institute in China Licensing Deal for Excella...

https://www.nugenerexio.com/ The “Complete Vaccine” for Cancer and Infectious Disease Ii-Key COVID Vaccine AE37 Immunotherapeutic Vaccine Management & Board of Directors Scientific Advisory Board MIRAMAR, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE)...

Ii-Key technology is safe, and in a breast cancer trial 10 years out, still effective. GNBT is negotiating contracts covering these areas: Malaysia, New Zealand, Australia, Southeast Asia, Singapore, South Africa, China, and Canada. Three trials of its vaccine are in the offing - ...

-Dr. Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM is the Derrol Dawkins, MD Endowed Chair in Adolescent Medicine at Children’s of Alabama, Professor of Pediatrics and Internal Medicine, Director of the University of Alabama at Birmingham Division of Adolescent Medicine, and Vice Chair ...

Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design Immunotherapy with cancer vaccines explained Review of cancer vaccine trials: design, results, opportunities Cancers 2020 , 12 (10), 2908; https://doi.org/10.3390/cancers12102908...

MIRAMAR, Fla., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for tomorrow’s investor conference call on Thursday October 8, 2020 at 8: 0 0 AM Eastern time . The access informati...

Bintai Kinden Corporation Berhad ( www.bintai.com.my ), an investment holding company headquartered in Malaysia will fund the U.S. Clinical Trials for the Ii-Key-SARS-CoV-2 vaccine against COVID-19 NuGenerex Immuno-Oncology has received the upfront licensing fee of $2.625 millio...

Co-Chairs to guide the development of Ii-Key-SARS-CoV-2 Vaccine as a safe & effective vaccine targeted for the pediatric population Dr. Jonathan Davis is Vice-Chair of Pediatrics and Chief of Newborn Medicine at Tufts Children’s Hospital and Professor of Pediatrics at Tuf...

Closing of licensing & distribution agreement with Bintai for COVID-19 vaccine in Malaysia Update on Ii-Key-SARS-CoV-2 vaccine development & international licensing opportunities COVID-19 Vaccine Scientific & Clinical Advisory Board Planed application to list NuG...